Geometric Deep learning Prioritization and Validation of Cannabis Phytochemicals as Anti-HCV Non-nucleoside Direct-acting Inhibitors
Introduction: The rate of acute hepatitis C increased by 7% between 2020 and 2021, after the number of cases doubled between 2014 and 2020. With the current adoption of pan-genotypic HCV therapy, there is a need for improved availability and accessibility of this therapy. However, double and triple...
Saved in:
| Main Authors: | Ssemuyiga Charles, Mulumba Pius Edgar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Biomedical Engineering and Computational Biology |
| Online Access: | https://doi.org/10.1177/11795972241306881 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immobilized Nucleoside 2′-Deoxyribosyltransferases from Extremophiles for Nucleoside Biocatalysis
by: Saúl Antonio Hernández Martínez, et al.
Published: (2024-12-01) -
Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief
by: Nicholas J. Wright, et al.
Published: (2024-12-01) -
DIRECT ACTING ANTIVIRAL TREATMENT FOR PATIENTS WITH END STAGE KIDNEY DISEASE WITH ACUTE HCV INFECTION
by: Nawfal R Hussein, et al.
Published: (2019-04-01) -
HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals
by: Erik J. Groessl, et al.
Published: (2017-01-01) -
Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
by: Grenda Leite Pereira, et al.
Published: (2019-01-01)